Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Sales of Investments

Cash received from selling or redeeming investments.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments grows, but more slowly than its trailing trend

Q1 FY2026 sales of investments of $290.26M rose 0.7% year over year, behind the +40.3% change in trailing-twelve-month sales of investments. Sequentially, it rose 15.1% from the prior quarter. Over 3 fiscal years it compounded at -3.4% a year.

Context

  • Sales of investments amounted to 1912.5% of revenue in FY2025, down 329.8 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.7% toward the trailing-twelve-month pace of +40.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$290.26M+15.1% QoQ
Last fiscal yearDec 2025
$1.03B+26.3% YoY
LTMMar 2026
$1.04B+40.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.7%——
1 year+26.3%——
3-year CAGR-3.4%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
1.03B USD
Year-over-year change
+26.3%
4-year CAGR
+5.6%

Sales of Investments vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 sales of investments of $1.04B is the 2nd largest of the 7 companies compared; the peer median is $381.97M.
  • Its year-over-year change of +40.3% is the 4th highest of 7, against a peer median of +50.3%.
  • Sales of investments amounts to 1567.4% of revenue for AGIO, versus a peer median of 39.2%.
AGIO Competitors Peer median
Sales of Investments for AGIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.34B +87.1%+18.2%132.6%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$1.04B +40.3%-3.4%1567.4%
IRONDisc Medicine, Inc.LTM Sep 2026$545.64M +39.0%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$395.01M -5.6%-6.6%59.0%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$368.93M +61.7%+29.8%39.2%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$125.56M +101.2%-19.0%20.3%
PHARPharming Group N.V.LTM Mar 2026$34.98M -87.9%—9.5%
Peer median (excluding AGIO) $381.97M+50.3%+5.8%39.2%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(356.51M)(231.8M)(352.09M)673.73M(412.78M)
Depreciation & Amortization9.24M8.56M6.62M5.65M5.18M
Deferred Income Tax00000
Stock-Based Compensation53.51M49.3M44.77M42.85M52.55M
Change in Working Capital(36.82M)(16.43M)(19.06M)(19.77M)(33.04M)
Accounts Receivables(4.38M)(2.21M)(604K)(1.3M)(6.47M)
Inventory0(8.49M)(10.58M)(8.54M)(5.3M)
Accounts Payables1.86M3.44M(8.73M)6.6M1.75M
Other Working Capital(34.31M)(9.17M)864K(16.53M)(23.02M)
Other Non-Cash Items(76.74M)(119.1M)23.69M(1.09B)15.12M
Operating Cash Flow(407.32M)(309.48M)(296.06M)(389.84M)(372.98M)
Capital Expenditures(5.74M)(4.88M)(999K)(1.69M)(4.32M)
Acquisitions (Net)0132.75M040K0
Purchases of Investments(1.38B)(1.03B)(417.93M)(1.54B)(641.76M)
Sales of Investments829.8M1.15B674.68M818.38M1.03B
Other Investing Activities1.8B0(16.18M)1.09B(10M)
Investing Cash Flow1.25B243.26M239.58M363.44M377.18M
Debt Repayment(578K)(331K)000
Common Stock Issued02.68M5.43M14.44M8.68M
Common Stock Repurchased(802.49M)0000
Dividends Paid00000
Other Financing Activities37.3M0000
Financing Cash Flow(765.77M)2.35M5.43M14.44M8.68M
Effect of Forex Changes00000
Net Change in Cash75.69M(63.87M)(51.05M)(11.96M)12.88M
Free Cash Flow(413.06M)(314.36M)(297.06M)(391.53M)(377.29M)

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.